Methamphetamine-Associated Pulmonary Arterial Hypertension in a Japanese Pulmonary Hypertension Referral Center
Authors:
Open Access
- 12 June 2026
- journal article
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 8 (8) , CR-26-0132-1369
Abstract
Background: Methamphetamine-associated pulmonary arterial hypertension (Meth-PAH) is increasingly recognized in Western countries, but Japanese data remain limited.Methods and Results: Of 363 patients with PAH, we identified 5 patients with Meth-PAH (1.4%); 4 were women, with a mean age of 37.6±7.2 years. Patients receiving PAH-specific therapy showed favorable hemodynamic responses, although 40% of patients experienced treatment discontinuation and methamphetamine reuse.Conclusions: In this case series of 5 Japanese patients with Meth-PAH, there was a high rate of treatment discontinuation and methamphetamine reuse, which suggests possible underdiagnosis of Meth-PAH and barriers to sustained care in Japan.Keywords
This publication has 4 references indexed in Scilit:
- Methamphetamine-associated PAH on the rise in the US: geographic trends & disparities in patient demographics and treatment strategiesThe Journal of Heart and Lung Transplantation, 2026
- Treatment Response and Survival in Methamphetamine‐Associated Pulmonary Arterial HypertensionJournal of the American Heart Association, 2025
- 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2022
- Features and Outcomes of Methamphetamine-associated Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2018